Imago BioSciences Raises $80 Million in Series C Financing
11/19/20, 1:04 PM
Location
san franciscoMoney raised
$80 million
Round Type
series c
Imago BioSciences, Inc. (“Imago”), a clinical-stage biopharmaceutical company developing innovative treatments for myeloproliferative neoplasms, today announced the close of an $80 million Series C financing round. Farallon Capital Management, LLC led the round, with participation from new investors including funds and accounts advised by T. Rowe Price Associates, Inc., funds and accounts managed by Blackrock Advisors, LLC., Surveyor Capital (a Citadel company), Irving Investors and Kingdon Capital Management
Company Info
Location
san francisco, california, united states
Additional Info
Bomedemstat is being evaluated in open-label Phase 2 clinical trials for the treatment of advanced myelofibrosis (MF), essential thrombocythemia (ET) and polycythemia vera, bone marrow cancers that alter the production of blood cells. MF patients who are resistant to, intolerant of, or ineligible for a Janus Kinase (JAK) inhibitor are eligible for the study of bomedemstat as monotherapy. Interim data will be presented in an oral session at the upcoming American Society of Hematology Annual Congress on December 5, 2020.